These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 1054886

  • 1. [Initial results with a epipodophyllotoxin derivative VP 16-213 in the treatment of acute leukemia].
    Cavalli F, Ryssel HJ, Batz K, Sonntag RW, Brunner KW.
    Schweiz Med Wochenschr; 1975 Feb 22; 105(8):250-3. PubMed ID: 1054886
    [Abstract] [Full Text] [Related]

  • 2. [Acute monocytic leukemia and acute myelomonocytic leukemia: treatment using VP 16213].
    Amiel JL, Schwarzenberg L, Musset M, De Vassal F, Hayat M, Mathé G.
    Bull Cancer; 1974 Feb 22; 61(3):419-26. PubMed ID: 4533742
    [No Abstract] [Full Text] [Related]

  • 3. [VP 16-213 in the treatment of acute leukemia in childhood].
    Esumi N, Arakawa S, Imashuku S.
    Gan To Kagaku Ryoho; 1983 Mar 22; 10(3):848-51. PubMed ID: 6576730
    [Abstract] [Full Text] [Related]

  • 4. [Acute leukemia and various hematosarcomas. Trial treatment with a second derivative of podophyllotoxin (4-demethyl-epipodophyllotoxin beta D ethylidene glucoside VP 16213 or EPE)].
    Mathé G, Schwarzenberg L, Pouillart P, Weiner R, Oldham R, Jasmin C, Rosenfeld C, Hayat M, Schneider M, Amiel JL, Céoara B, Steresco-Musset M, de Vassal F.
    Nouv Presse Med; 1974 Mar 02; 3(9):521-4. PubMed ID: 4595555
    [No Abstract] [Full Text] [Related]

  • 5. [Acute monocytic and myelomonocytic leukemias. Incidence and treatment with an epipodophyllotoxin derivative (VP 16.213)].
    Bernasconi C, Lazzarino M, Morra E.
    Recenti Prog Med; 1975 Oct 02; 59(4):372-87. PubMed ID: 769106
    [No Abstract] [Full Text] [Related]

  • 6. [Our experiences in the treatment of acute leukemias].
    Jelić S, Dragović M, Vidaković B, Plecas V.
    Bilt Hematol Transfuz; 1976 Oct 02; 4(1-2):87-95. PubMed ID: 1066129
    [Abstract] [Full Text] [Related]

  • 7. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K, Ogawa M, Kimura I, Ohnoshi T, Yamada K, Masaoka T, Wakui A, Meguro S, Nagai K, Kitani T.
    Gan To Kagaku Ryoho; 1986 Oct 02; 13(10):3021-7. PubMed ID: 3464230
    [Abstract] [Full Text] [Related]

  • 8. High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
    Van Echo DA, Wiernik PH, Aisner J.
    Cancer Clin Trials; 1980 Oct 02; 3(4):325-8. PubMed ID: 6933027
    [Abstract] [Full Text] [Related]

  • 9. Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas.
    Mathé G, Schwarzenberg L, Pouillart P, Oldham R, Weiner R, Jasmin C, Rosenfeld C, Hayat M, Misset JL, Musset M, Schneider M, Amiel JL, De Vassal F.
    Cancer; 1974 Oct 02; 34(4):985-92. PubMed ID: 4608026
    [No Abstract] [Full Text] [Related]

  • 10. Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine.
    Look AT, Dahl GV, Kalwinsky D, Senzer N, Mason C, Rivera G.
    Cancer Treat Rep; 1981 Oct 02; 65(11-12):995-9. PubMed ID: 6170431
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours.
    European Organization for Research on the Treatment of Cancer, Clinical Screening Group.
    Br Med J; 1973 Jul 28; 3(5873):199-202. PubMed ID: 4578134
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Results of treatment of acute luekemia in adults according to our records].
    Kotlarek-Haus S, Witkowska M, Kuliszkiewicz M.
    Acta Haematol Pol; 1975 Jul 28; 6(1):51-8. PubMed ID: 1054903
    [Abstract] [Full Text] [Related]

  • 17. Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213.
    Schiffer CA, DeBellis R, Kasdorf H, Wiernik PH.
    Cancer Treat Rep; 1982 Feb 28; 66(2):267-71. PubMed ID: 6173123
    [Abstract] [Full Text] [Related]

  • 18. [Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].
    Jungi WF, Senn HJ, Beckmann C, Flury R, Frei P, Holdener E.
    Schweiz Med Wochenschr; 1975 Oct 18; 105(42):1365-9. PubMed ID: 179137
    [Abstract] [Full Text] [Related]

  • 19. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
    Esumi N, Todo S, Arakawa S, Imashuku S.
    Gan To Kagaku Ryoho; 1986 Apr 18; 13(4 Pt 1):951-8. PubMed ID: 3963859
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
    Bleyer WA, Krivit W, Chard RL, Hammond D.
    Cancer Treat Rep; 1979 Jun 18; 63(6):977-81. PubMed ID: 380803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.